Effect of polyoma viremia on 3‐year allograft kidney function

AbstractBackgroundPolyoma viremia is associated with damage to renal tubular and urothelial cells. This may imply that a certain level of viremia, even cleared thereafter, could be associated with long‐term renal dysfunction.MethodsWe, retrospectively, analyzed 390 first renal transplants adult recipients (≥18 years) who were monitored for BK viremia in the first 12 months and evaluated estimated GFR (MDRD‐4 equation) at 1 month and at the last follow‐up (959 ± 392 days).ResultsOne hundred and ninety‐nine patients (51%) developed at least one positive viremia: 105 (53%) low viremia (<104 copies/mL), 36 (18%) high viremia (4 × 104 > viremia ≥ 104 copies/mL) and 58 (15%) viremia (≥4 × 104 copies/mL) consistent with polyoma virus associated nephropathy (PyVAN). Out of these 58 patients, 24 (6%) developed bx‐proven (SV40+) PyVAN and 34(8.7%) presumptive PyVAN (SV40−). Baseline characteristics, immunosuppression, KDRI, rejection episodes, etc., did not differ among groups but there were more deceased donors and ATG induction therapy in the high viremia group. At last follow‐up, all patients in the low, high viremia and presumptive PyVAN (except 2) had cleared BK viremia. Bx‐proven PyVAN led to 14 graft losses, 10 due to PyVAN. In the presumptive PyVAN there was only one graft loss registered as due to PyVAN. eGFR, at 1 month after KTx, did not differ among groups (51 ± 22 vs 48 ± 24 vs 45 ± 27 vs 43 ± 18 vs 46 ± 22 mL/min/1.73 m2), for no, low and high viremia as well for presumptive PyVAN and bx‐proven PyVAN groups, respectively. At the last follow‐up, eGFR did not differ between the no, low, and high viremia compared to baseline and to each other but was statistically lower in the presumptive and bx‐proven PyVAN (38 ± 15 and 17 ± 7 mL/min/1.73 m2) either compared to baseline or to the other groups.ConclusionsThis study shows that low and high levels of BK viremia do not lead to GFR changes although very high viremia levels, compatible with presumptive or bx‐proven PyVAN, even if cleared thereafter, lead to allograft damage and decreased GFR.